BATM Advanced Communications Limited (LON:BVC) has said its test kit for coronavirus (COVID-19) is effective at diagnosing a new variant of the virus that is rapidly spreading in the UK and elsewhere.
The networking and medical laboratory solutions firm said that it continually tests its kits against any mutations of the virus that are perceived to be clinically material to ensure they are accurately able to detect all known variants of COVID-19.
READ: BATM unveils investment into Ador Diagnostics to speed up development of rapid testing technology
BATM added that the kits also have 4+1 gene discovery capability compared with a market standard of one to three gene discovery, which enables it to provide more accurate results and reduce the risk of false positives and false negatives.
The company is now offering its 4+1 kit as its standard COVID-19 antigen test, which is being delivered to several private and government customers in Europe and elsewhere.
"I am pleased to confirm that our COVID-19 tests are effective in accurately detecting all COVID-19 variants, including in those infected with this latest mutation. Viruses constantly change through mutation and our diagnostics platform has been built on our recognition that we must always think of the future. As a result, we were able to rapidly develop COVID-19 tests in response to the outbreak and those kits have been designed to be effective against the emergence of new variants", BATM chief executive Zvi Marom said in a statement.